Long-term efficacy, safety, and tolerability of a subcutaneous immunoglobulin 16.5% (cutaquig®) in the treatment of patients with primary immunodeficiencies.
Saved in:
| Title: | Long-term efficacy, safety, and tolerability of a subcutaneous immunoglobulin 16.5% (cutaquig®) in the treatment of patients with primary immunodeficiencies. |
|---|---|
| Authors: | Kobayashi RH; UCLA School of Medicine, Los Angeles, CA, USA., Litzman J; Department of Clinical Immunology and Allergology, St Anne's University Hospital in Brno, Faculty of Medicine, Masaryk University, Brno, Czechia., Melamed I; IMMUNOe Research Center, Centennial, CO, USA., Mandujano JF; Pediatric Pulmonary Associates of North Texas, Frisco, TX, USA., Kobayashi AL; Midlands Pediatrics, Papillion, NE, USA., Ritchie B; Division of Hematology, Department of Medicine, University of Alberta Hospital, Edmonton, AB, Canada., Geng B; Divisions of Allergy and Immunology, University of California San Diego, La Jolla, CA, USA., Atkinson TP; Department of Pediatric Allergy, Asthma and Immunology, University of Alabama, Birmingham, AL, USA., Rehman S; Allergy and Asthma Center Inc., Toledo, OH, USA., Höller S; Octapharma Pharmazeutika Produktionsges.m.b.H., Vienna, Austria., Turpel-Kantor E; Octapharma Pharmazeutika Produktionsges.m.b.H., Vienna, Austria., Kreuwel H; Octapharma US, Paramus, NJ, USA., Speer JC; Octapharma US, Paramus, NJ, USA., Gupta S; Division of Basic and Clinical Immunology, University of California Irvine, Irvine, CA, USA. |
| Source: | Clinical and experimental immunology [Clin Exp Immunol] 2022 Dec 15; Vol. 210 (2), pp. 91-103. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 0057202 Publication Model: Print Cited Medium: Internet ISSN: 1365-2249 (Electronic) Linking ISSN: 00099104 NLM ISO Abbreviation: Clin Exp Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
